Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Genprex Inc.

Headquarters: Austin, TX, United States of America
Year Founded: 2009
Status: Public
Industry Sector: HealthTechnology
CEO: Ryan M. Confer
Number Of Employees: 15
Enterprise Value: $1,809,844
PE Ratio: -0.05
Exchange/Ticker 1: NASDAQ:GNPX
Exchange/Ticker 2: N/A
Latest Market Cap: $3,672,100

BioCentury | Aug 3, 2024
Deals

Biotechs find problem-solving in academia, and mostly outside the big hubs 

Academia-biotech deals span innovative assets to tissue bank resources to enabling technologies
BioCentury | Feb 25, 2023
Discovery & Translation

De novo enzyme design; plus base editing for hypertrophic cardiomyopathy and more

BioCentury’s roundup of translational news
BioCentury | Sep 28, 2021
Management Tracks

New hires at Brii, Ono and PharmaEssentia to strengthen U.S. leadership

Plus: Ocular, Genprex, SAB and more
BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

Kriya plans to extend gene therapies to prevalent, chronic diseases
BioCentury | Jul 28, 2017
Financial News

Genprex proposes $24.5M IPO

BioCentury | Jan 27, 2017
Clinical News

Oncoprex: Interim Ph II data

BioCentury | Apr 23, 2012
Clinical News

Genprex preclinical data

Items per page:
1 - 8 of 8